期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Codelivery of dihydroartemisinin and chlorin e6 by copolymer nanoparticles enables boosting photodynamic therapy of breast cancer with low-power irradiation
1
作者 Jing Jia Wenping Chen +11 位作者 Long Xu Xuewen Wang Min Li Bin Wang Xiangyu Huang Tao Wang Yang Chen Mengdie Li Dan Tian Junyang Zhuang Xinhua Lin Ning Li 《Regenerative Biomaterials》 SCIE EI CSCD 2023年第1期1060-1072,共13页
Given that chemotherapy as a stand-alone therapeutic strategy may not be sufficient to effectively treat cancer,there is increasing interest in combination of chemotherapy and alternative therapies.Photodynamic therap... Given that chemotherapy as a stand-alone therapeutic strategy may not be sufficient to effectively treat cancer,there is increasing interest in combination of chemotherapy and alternative therapies.Photodynamic therapy has the advantages of high selectivity and low side effects,so the combination of photodynamic therapy and chemotherapy has become one of the most appealing strategies for tumor treatment.In this work,we constructed a nano drug codelivery system(PPDC)to realize the combined treatment of chemotherapy and photodynamic therapy through encapsulating chemotherapeutic drug dihydroartemisinin and photosensitizer chlorin e6 in PEG-PCL.The potentials,particle size and morphology of nanoparticles were characterized by dynamic light scattering and transmission electron microscopy.We also investigated the reactive oxygen species(ROS)generation and drug release ability.The antitumor effect in vitro was investigated by methylthiazolyldiphenyl-tetrazolium bromide assays and cell apoptosis experiments,and the potential cell death mechanisms were explored by ROS detection and Western blot analysis.The in vivo antitumor effect of PPDC was evaluated under the guidance of fluorescence imaging.Our work provides a potential antitumor treatment approach and expands the application of dihydroartemisinin for breast cancer therapy. 展开更多
关键词 DIHYDROARTEMISININ photodynamic therapy combination therapy nano drug delivery systems
原文传递
Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
2
作者 Xiaolan Xu Jiaming Zhang +10 位作者 Tao Wang Jing Li Yukang Rong Yanfang Wang Chenxia Bai Qing Yan Xiaohua Ran Yingli Wang Tianhong Zhang Jin Sun Qikun Jiang 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2024年第4期1542-1559,共18页
The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins.In recent years,toxins have been widely used as warheads for antibody-drug conjugates(ADCs)due to their eff-cient killing activity a... The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins.In recent years,toxins have been widely used as warheads for antibody-drug conjugates(ADCs)due to their eff-cient killing activity against various cancer cells.Although ADCs confer certain targeting properties to the toxins,low drug loading capacity,possible immunogenicity,and other drawbacks also limit the po-tential application of ADCs.Recently,non-ADC delivery strategies for toxins have been extensively investigated.To further understand the application of toxins in anti-tumor,this paper provided an over-view of prodrugs,nanodrug delivery systems,and biomimetic drug delivery systems.In addition,toxins and their combination strategies with other therapies were discussed.Finally,the prospect and challenge of toxins in cancertreatmentwerealso summarized. 展开更多
关键词 TOXINS Non-antibody-drug conjugates delivery strategies PROdrugS nano drug delivery systems Biomimetic drugdelivery systems Combination strategies Cancer treatment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部